Skip to main content

Table 1 Baseline patient characteristics according to dialysis modality and initiation pattern for first time dialysis

From: Comparison of outcomes between emergent-start and planned-start peritoneal dialysis in incident ESRD patients: a prospective observational study

 

All

PD

HD

Planned-start

Emergent-start

p value

Planned-start

Emergent-start

p value

AVF/AVG

CVC

N

507

43

68

–

116

243

37

–

Men, n (%)

288 (56.8)

21 (48.8)

40 (58.8)

0.303a

65 (56.0)

140 (57.6)

22 (59.5)

0.925a

Age, years, n (%)

61.8 ± 15.5

52.1 ± 10.2

49.3 ± 13.3

0.327b

67.3 ± 13.2

63.8 ± 14.6

61.8 ± 15.5

0.075d

 ≧65

233 (44.0)

4 (9.3)

8 (11.8)

0.763c

69 (59.5)

119 (49.0)

23 (62.2)

0.092a

Predialysis education program

281 (55.4)

32 (74.4)

30 (44.1)

0.002a

106 (91.4)*#

100 (41.2)*

13 (35.1)#

< 0.001a

Primary renal diseases, n (%)

 Diabetes mellitus

217 (42.8)

10 (23.3)

17 (25.0)

0.835a

56 (48.3)

119 (49.0)

15 (40.5)

0.631a

 Glomerulonephritis

115 (22.7)

16 (37.2)

30 (44.1)

0.472a

18 (15.5)

42 (17.3)

9 (24.3)

0.467a

 Others

175 (34.5)

17 (39.5)

21 (30.9)

0.349a

42 (36.2)

82 (33.7)

13 (35.1)

0.898a

Comorbidities, n (%)

 Diabetes mellitus

247 (48.7)

12 (27.9)

19 (27.9)

0.997a

60 (51.7)

139 (57.2)

17 (45.9)

0.338a

 Hypertension

426 (84.0)

38 (88.4)

56 (82.4)

0.391a

99 (85.3)

207 (85.2)

26 (70.3)

0.062a

 Hyperlipidemia

117 (23.1)

9 (20.9)

23 (33.8)

0.144a

27 (23.3)

48 (19.8)

10 (27.0)

0.515a

 CAD

65 (12.8)

4 (9.3)

9 (13.2)

0.763c

10 (8.6)

34 (14.0)

8 (21.6)

0.102a

 CHF

80 (15.8)

3 (7.0)

11 (16.2)

0.241c

10 (8.6)*

50 (20.6)*

6 (16.2)

0.018a

 VHD

25 (4.9)

1 (2.3)

2 (2.9)

1.000c

2 (1.7)

16 (6.6)

4 (10.8)

0.058a

 CVA

44 (8.7)

2 (4.7)

1 (1.5)

0.558c

12 (10.3)

21 (8.6)

8 (21.6)

0.054a

 PAOD

27 (5.3)

1 (2.3)

5 (7.4)

0.402c

5 (4.3)

14 (5.8)

2 (5.4)

0.848a

 Cancer

44 (8.7)

2 (4.7)

1 (1.5)

0.558c

13 (11.2)#

19 (7.8)$

9 (24.3)#$

0.008a

Laboratory parameters

 Creatinine, mg/dl

12.3 ± 5.1

12.6 ± 4.0

15.4 ± 6.1

0.008b

11.2 ± 4.0

12.1 ± 5.1

12.3 ± 5.1

0.057d

 eGFR, ml/min/1.73 m2

4.1 ± 1.8

3.9 ± 1.8

3.6 ± 2.0

0.111b

4.1 ± 1.6#

4.1 ± 1.8$

5.1 ± 2.2#$

0.020d

 Albumin, g/dl

3.6 ± 0.6

4.1 ± 0.5

3.7 ± 0.5

0.002b

3.8 ± 0.5*#

3.4 ± 0.6*

3.6 ± 0.6#

< 0.001d

 Hemoglobin, g/dl

8.7 ± 1.6

9.1 ± 1.4

8.4 ± 1.9

0.130e

9.3 ± 1.4*

8.3 ± 1.5*

8.7 ± 1.6

< 0.001f

 Potassium, mmol/l

4.6 ± 0.9

4.5 ± 0.7

4.7 ± 0.9

0.365b

4.5 ± 0.8

4.7 ± 1.0

4.6 ± 0.9

0.395d

 Phosphorus, mg/dl

6.7 ± 2.2

5.8 ± 1.5

7.7 ± 2.5

< 0.001b

5.9 ± 1.9*

6.8 ± 2.2*

6.7 ± 2.2

0.010d

  1. Abbreviations: CAD coronary artery disease, CHF congestive heart failure, VHD valvular heart disease, CVA cerebrovascular accident, PAOD peripheral arterial occlusive disease. a χ2; b Mann-Whitney U test; c Fisher’s exact test; d Kruskal–Wallis H test; e t-test; f ANOVA. *, #, $ p < 0.05